Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Key Points The transaction involved the disposal of 7,500 shares. The disposition resulted in a 2% reduction in the insider's total equity holdings. The transaction was structured as a direct exercise and sale of 7,500 shares, while 4,166 shares remain held indirectly through the Bridget Blum and Brittany Blum 2003 Irrevocable Trusts. 10 stocks we like better than Cytokinetics › Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK) , reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing . Transaction summary Metric Value Transaction value $575,700 Shares sold (direct) 7,500 Post-transaction shares (directly held) 377,820 Post-transaction shares (indirectly held) 4,166 Transaction value based on SEC Form 4 weighted average sale price ($76.76); post-transaction value based on Aug. 10, 2026, market close ($77.49). Key questions What were the specific mechanics of this derivative transaction? Robert I. Blum exercised 7,500 stock options at a strike price of $10.60 per share and immediately sold the resulting shares at a weighted-average price of $76.76, a move that captures the appreciation from the grant price and current market levels. How does the CEO's remaining equity exposure compare to the transaction size? Despite the sale, the CEO retains a substantial position comprising 377,820 direct shares and approximately 172,000 derivative securities, ensuring a continued alignment with shareholder interests. Are there other entities through which the CEO maintains an equity position? Yes, the CEO holds 4,166 shares indirectly, which are distributed equally between the Bridget Blum 2003 Irrevocable Trust and the Brittany Blum 2003 Irrevocable Trust. What is the company's financial profile relative to this insider activity? Cytokinetics maintains a market capitalization of $9.6 billion as of the Aug. 10, 2026, transaction date, supported by trailing twelve-month revenue of $71.0 million against a net loss of -$894.0 million. Company Overview Metric Value Share Price (as of market close 2026-08-07) $76.76 Market Capitalization $10.6 billion Revenue (TTM) $67.6 million Net Income (TTM) -$894 million Company Snapshot Cytokinetics develops and commercializes novel muscle activators and muscle inhibitors, with MYQORZO generating revenue as an FDA-approved oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, while advancing a pipeline including Aficamten and omecamtiv mecarbil for additional cardiac indications. The company operates a biopharmaceutical business model focused on discovering and developing proprietary small-molecule therapeutics, generating revenue through product sales while investing substantially in the clinical development and commercialization of its pipeline candidates. Cytokinetics primarily targets cardiologists and patients suffering from debilitating cardiac conditions, including hypertrophic cardiomyopathy and heart failure, with a geographic focus on the United States market. Cytokinetics is a clinical-stage biopharmaceutical company with a market capitalization of $10.6 billion, leveraging its proprietary muscle modulation platform to develop innovative cardiac therapeutics. The company has achieved commercial traction with MYQORZO while maintaining a robust pipeline of muscle-targeted candidates designed to address significant unmet medical needs in cardiology. With a strategic focus on cardiac indications, Cytokinetics positions itself at the intersection of precision medicine and cardiovascular treatment innovation. What this transaction means for investors This transaction, given the context of exercising stock options and the price at which it was exercised, largely appears to be routine. As of this writing, over the last 12 months, Cytokinetics' stock price has climbed 100%, easily outpacing the S&P 500's 18.6% return. That would align with Bloom just wanting to exercise those 7,500 stock options at a strike price of $10.60 to capture some of the gains, as the stock is trading for $76.84 per share. He still holds 377,820 shares directly and 4,166 shares indirectly, indicating continued alignment with the company's success. Bloom's sale is not a signal that something may be amiss with the company. For shareholders, analysts still view the stock favorably. Of the 23 analysts who track Cytokinetics, 91% rate the stock a buy, while 9% rate it a hold. The median one-year average price target is $107.50, which, if the stock were to reach it, would be a gain of nearly 40%. The highest price target is $146, while the lowest is $85. Should you buy stock in Cytokinetics right now? Before you buy stock in Cytokinetics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cytokinetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $429,223 !* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,318,055 !* Now, it’s worth noting Stock Advisor’s total average return is 965 % — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 22, 2026. Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Cytokinetics. The Motley Fool has a disclosure policy .

The disposition resulted in a 2% reduction in the insider's total equity holdings.

The transaction was structured as a direct exercise and sale of 7,500 shares, while 4,166 shares remain held indirectly through the Bridget Blum and Brittany Blum 2003 Irrevocable Trusts.

Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK) , reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing .

Transaction value based on SEC Form 4 weighted average sale price ($76.76); post-transaction value based on Aug. 10, 2026, market close ($77.49).

Cytokinetics is a clinical-stage biopharmaceutical company with a market capitalization of $10.6 billion, leveraging its proprietary muscle modulation platform to develop innovative cardiac therapeutics. The company has achieved commercial traction with MYQORZO while maintaining a robust pipeline of muscle-targeted candidates designed to address significant unmet medical needs in cardiology. With a strategic focus on cardiac indications, Cytokinetics positions itself at the intersection of precision medicine and cardiovascular treatment innovation.

This transaction, given the context of exercising stock options and the price at which it was exercised, largely appears to be routine. As of this writing, over the last 12 months, Cytokinetics' stock price has climbed 100%, easily outpacing the S&P 500's 18.6% return. That would align with Bloom just wanting to exercise those 7,500 stock options at a strike price of $10.60 to capture some of the gains, as the stock is trading for $76.84 per share. He still holds 377,820 shares directly and 4,166 shares indirectly, indicating continued alignment with the company's success. Bloom's sale is not a signal that something may be amiss with the company. For shareholders, analysts still view the stock favorably. Of the 23 analysts who track Cytokinetics, 91% rate the stock a buy, while 9% rate it a hold. The median one-year average price target is $107.50, which, if the stock were to reach it, would be a gain of nearly 40%. The highest price target is $146, while the lowest is $85.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Cytokinetics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.